CQDM welcomes its new “Network” Member, Simmunome Inc.
Simmunome untangles biological complexity by developing in silico disease models that accurately capture physiological processes to predict efficacy and safety of potential treatments. In addition, our algorithms use a comprehensive multiomic approach to discover new targets and biomarkers for a disease or a certain patient population.
More information on their website: https://www.simmunome.com/
We invite you to learn more about this new “Network” Members as well as the advantages related to this type of CQDM membership via this link:
Biopharmaceutical consortium members | CQDM